1013 related articles for article (PubMed ID: 29562226)
1. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
2. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
3. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
Seeber A; Gunsilius E; Gastl G; Pircher A
Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J; Desai J
Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
[TBL] [Abstract][Full Text] [Related]
5. VEGF signaling in cancer treatment.
Sia D; Alsinet C; Newell P; Villanueva A
Curr Pharm Des; 2014; 20(17):2834-42. PubMed ID: 23944367
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
8. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
9. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
11. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
12. A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition.
Labanca V; Bertolini F
EBioMedicine; 2016 Aug; 10():13-4. PubMed ID: 27506898
[No Abstract] [Full Text] [Related]
13. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
14. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
Adjei AA
Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S74-8. PubMed ID: 17382028
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor a inhibition in gastric cancer.
Park DJ; Thomas NJ; Yoon C; Yoon SS
Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and bevacitumab in breast cancer.
Bando H
Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
[TBL] [Abstract][Full Text] [Related]
17. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
Grépin R; Pagès G
J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
[TBL] [Abstract][Full Text] [Related]
18. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
Sharma PS; Sharma R; Tyagi T
Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis in Colorectal Cancer: Antibodies.
Chan E
Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
[TBL] [Abstract][Full Text] [Related]
20. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
Zhang C; Tan C; Ding H; Xin T; Jiang Y
Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
